Many medical devices need to be sterile to be used safely. But sterilizing a pacemaker, catheter, or other device with steam or heat could damage its structural integrity. So medical device manufacturers turn to the chemical compound ethylene oxide, which is highly effective at killing microbes at low concentrations and allows companies to meet the Food and Drug Administration’s strict sterility standards. As a result, roughly half of all medical devices in the country are sterilized with ethylene oxide, or EtO, making it a linchpin of the medical device industry.
There’s just one problem: EtO is a toxic gas that has been linked to cancers of the breast and lymph nodes. Roughly 90 facilities across the country deploy the chemical for sterilization. These nondescript facilities often resemble warehouses and are located in residential neighborhoods and near schools.
In 2022, the Environmental Protection Agency discovered that dozens of these facilities presented an unacceptable cancer risk to surrounding communities. Two years later, the federal agency, led at the time by the Biden administration, announced new regulations to limit the amount of the chemical released into the air. The rule required sterilization facilities to install equipment to capture and burn ethylene oxide and was estimated to cut EtO emissions — and the resulting cancer risk to nearby communities — by more than 90 percent.
But after the sterilization industry protested that the rule was too burdensome, the newly-elected Trump administration began rolling it back. Last year, Trump exempted many facilities from having to comply with the rule. And this week, the EPA moved to repeal the rule altogether.
“This proposed rule shows EPA’s strong commitment to protecting people’s health while maintaining a stable domestic medical supply chain,” said EPA Administrator Lee Zeldin, in a press release. “The Trump EPA is committed to ensuring life-saving medical devices remain available for the critical care of America’s children, elderly, and all patients without unnecessary exposure to communities.”
When the Biden administration formalized sterilization rules in 2024, companies began taking steps to meet an April 2026 compliance deadline. In fact, 7 of the 88 sterilization facilities across the country already met the standards at the time they were passed. Others began installing equipment to capture ethylene oxide. A spokesperson for AdvaMed, the industry group that represents sterilizers, previously told Grist that, even before the 2024 rule was finalized, sterilizers had undertaken “extensive efforts to implement state-of-the-art upgrades, allowing for continued safe use of EtO in order to meet and even exceed regulations.”
Still, the industry was eager to find a way around the regulations. After the EPA set up a special inbox last year to receive requests for exemptions from several Clean Air Act provisions, including rules for ethylene oxide emissions, the sterilization industry flooded it with petitions. Trump eventually granted exemptions to about 40 facilities last year. A group of environmental nonprofits and community groups has sued Trump and the EPA over the decision.
“We always knew the presidential exemptions issued last year were part of a broader plan to put the interests of corporate polluters above the health and well-being of American families,” said Maurice Carter, president of Sustainable Newton, a Georgia-based environmental advocacy group, in a press release. “But we won’t stop fighting to protect our community by demanding commonsense, reasonable measures.”
The EPA said its latest move is necessary to protect the domestic supply chain of critical medical equipment. In a press release announcing the proposal, the agency said it is committed to ensuring that its “regulation will not put countless lives at risk,” noting that no viable alternative to ethylene oxide currently exists.
While it is true that alternatives to ethylene oxide do not currently exist, the sterilizers have several other options to reduce emissions while continuing to use the gas. In some cases, facilities tend to overapply ethylene oxide in a process called “overkill” to ensure a high margin of safety. This method is designed to exceed the level needed to meet sterility standards. Reducing these doses can lead to lower emissions. Facilities have also largely adapted to the more stringent regulations by installing so-called Permanent Total Enclosures. This technology traps ethylene oxide inside the building and funnels it to an oxidizer that burns the gas before it can escape. It is estimated to be 99 percent effective.
But in letters to the EPA and other public-facing statements, the industry has said PTEs are technically challenging to install and expensive. Ultimately, the EPA rule will “jeopardize the availability of sterile medical devices and supplies” and “will likely result in a significant disruption and public healthcare crisis,” the industry group AdvaMed said in a 2023 letter.
“With hundreds of thousands of surgeries and other medical procedures performed across the United States every day, the ability to meet those demands is essential,” AdvaMed president Scott Whitaker said in a statement sent to Grist. “We appreciate the EPA’s efforts in listening to and understanding the importance of supplying safe, sterile medtech without interruption while protecting employees and communities near sterilization facilities.”
In its latest proposal, the EPA is also questioning the toxicity of ethylene oxide. The EPA found that the chemical was 30 times more toxic to adults and 60 times more toxic to children than previously understood in 2016. That finding prompted a series of actions to inform the public about the risks sterilizers posed and eventually led to the 2024 standards. But the Trump administration now appears to be questioning the underlying toxicity data that was used to justify more stringent regulations.
In its press release, the agency said that ethylene oxide is “produced within the body via normal processes and additionally from tobacco smoke or other combustion processes” and that “new information” about the chemical has continued to emerge. The agency also plans to “consider comments” about the Texas Commission on Environmental Quality’s toxicity assessment for ethylene oxide. The Texas agency has long held that the chemical is far less toxic than the EPA’s assessments.
Facts Only
* The Environmental Protection Agency (EPA) regulates the sterilization of medical devices, primarily using ethylene oxide (EtO).
* Roughly half of all medical devices in the United States are sterilized with EtO.
* The sterilization industry relies heavily on EtO due to its effectiveness and low concentrations needed for sterility.
* Ethylene oxide is a toxic gas linked to increased cancer risks.
* Ninety facilities across the country operate EtO sterilization processes.
* The Biden administration issued new regulations in 2024 to limit EtO emissions, requiring facilities to install capture and burn equipment.
* These regulations were estimated to cut EtO emissions by more than 90 percent.
* The Trump administration rolled back the 2024 regulations, exempting many facilities.
* The EPA moved to repeal the 2024 rule altogether.
* The EPA Administrator stated the move is to protect public health while maintaining a stable medical supply chain.
* Seven of the 88 sterilization facilities already met the standards at the time they were passed.
* The industry group AdvaMed expressed concerns that the regulations would disrupt the supply of sterile medical devices.
* The EPA found that ethylene oxide is 30 times more toxic to adults and 60 times more toxic to children than previously understood.
* Facilities have implemented Permanent Total Enclosures (PTEs) to trap ethylene oxide, estimated to be 99 percent effective.
* The industry argues PTEs are technically challenging and expensive.
* The EPA is questioning the toxicity of ethylene oxide, citing findings from the Texas Commission on Environmental Quality.
Executive Summary
Full Take
Patterns detected: ARC-0043 Motte-and-Bailey, ARC-0024 Ambiguity, ARC-0018 False Framing
The article presents a deeply familiar narrative: a powerful industry resisting regulation, fueled by a perceived threat to its operations. The core framing is a binary – “safe, sterile medtech without interruption” versus “putting countless lives at risk” – a classic Motte-and-Bailey tactic designed to deflect criticism by exaggerating the potential negative consequences while downplaying the established risks of EtO. The industry’s emphasis on “stability” and “critical care” evokes a moral panic, framing the issue as an existential threat to patient health, which serves as a potent emotional hook. This is compounded by the ‘false framing’ of an immediate, unavoidable crisis – the claim that no viable alternatives currently exist—which is a deliberately misleading tactic. The repeated invocation of the EPA’s “commitment” rings hollow when juxtaposed with the industry’s aggressive lobbying and subsequent rollbacks.
The underlying paradigm is a classic battle between corporate interests and public safety, one that has played out repeatedly across environmental and public health debates. It’s rooted in a fundamental assumption – that economic activity must always supersede health concerns – a deeply problematic and potentially dangerous philosophical stance. The industry’s insistence on PTEs, presented as a “state-of-the-art” solution, masks a deeper problem: an unwillingness to accept any restrictions on EtO usage, even if it means prolonged exposure to toxic chemicals. The repeated “just asking questions” rhetoric from both sides, particularly regarding the toxicity of EtO, suggests a deliberate obfuscation of the issue, creating an ambiguity around the level of risk. It's a systemically driven move to delay meaningful action, using scientific uncertainty as a shield against accountability.
The implications extend beyond the immediate issue of medical device sterilization. It highlights the structural vulnerability of regulatory frameworks to corporate influence and the tendency of powerful industries to prioritize profit over public well-being. The speed with which the Trump administration overturned the 2024 rules suggests a deliberate, coordinated effort to undermine public health protections. It also illustrates the challenge of balancing competing interests – in this case, the availability of medical devices versus the safety of surrounding communities.
Questions: How can we build regulatory systems that are truly resistant to corporate capture? What alternative frameworks can we develop to prioritize public health over short-term economic gains? Does this case reveal a broader trend of regulatory capture in the healthcare sector?
Counterstrike Scan: The article's presentation mirrors a common influence campaign tactic: leveraging public anxiety around medical care to bolster support for continued industrial practices. A bad actor would amplify the claims of disruption to the medical supply chain, deliberately creating a sense of crisis and urgency – mirroring the language used in this piece – to justify the industry's position. The amplification of “technical challenges” with PTEs would further solidify this narrative, effectively using manufactured complexity to delay action and discredit alternative approaches.
Sentinel — Likely Human
The text presents a detailed account of the shifting regulatory landscape surrounding ethylene oxide sterilization, employing a balanced structure that leans toward minimizing concerns about public health risks. Subtle stylistic indicators, coupled with a framing that emphasizes industry cooperation, suggest a human-authored effort to navigate complex political and technical issues.